These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


369 related items for PubMed ID: 23915220

  • 21. LncRNA HOTAIR participates in the development and progression of adrenocortical carcinoma via regulating cell cycle.
    Yan ZC, He L, Qiu JH, Deng WT, Lu JR, Yuan Z, Liu DJ, Zheng RQ, Jiang W.
    Eur Rev Med Pharmacol Sci; 2018 Oct; 22(20):6640-6649. PubMed ID: 30402836
    [Abstract] [Full Text] [Related]

  • 22. Stathmin 1 is highly expressed and associated with survival outcome in malignant adrenocortical tumours.
    Dos Santos Passaia B, Lima K, Kremer JL, da Conceição BB, de Paula Mariani BM, da Silva JCL, Zerbini MCN, Fragoso MCBV, Machado-Neto JA, Lotfi CFP.
    Invest New Drugs; 2020 Jun; 38(3):899-908. PubMed ID: 31441020
    [Abstract] [Full Text] [Related]

  • 23. Aberrant CpG island hypermethylation of RASSF1A in gastric cardia adenocarcinoma.
    Guo W, Dong Z, Chen Z, Yang Z, Wen D, Kuang G, Guo Y, Shan B.
    Cancer Invest; 2009 May; 27(4):459-65. PubMed ID: 19160099
    [Abstract] [Full Text] [Related]

  • 24. Promoter hypermethylation of DNA damage response genes in hepatocellular carcinoma.
    Li Z, Zhang H, Yang J, Hao T, Li S.
    Cell Biol Int; 2012 May 01; 36(5):427-32. PubMed ID: 21864295
    [Abstract] [Full Text] [Related]

  • 25. Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma.
    Schagdarsurengin U, Gimm O, Hoang-Vu C, Dralle H, Pfeifer GP, Dammann R.
    Cancer Res; 2002 Jul 01; 62(13):3698-701. PubMed ID: 12097277
    [Abstract] [Full Text] [Related]

  • 26. Hypermethylation-modulated downregulation of RASSF1A expression is associated with the progression of esophageal cancer.
    Mao WM, Li P, Zheng QQ, Wang CC, Ge MH, Hu FJ, Fang XH, Dong ZM, Ling ZQ.
    Arch Med Res; 2011 Apr 01; 42(3):182-8. PubMed ID: 21722812
    [Abstract] [Full Text] [Related]

  • 27. Cellular landscape of adrenocortical carcinoma at single-nuclei resolution.
    Tourigny DS, Altieri B, Secener KA, Sbiera S, Schauer MP, Arampatzi P, Herterich S, Sauer S, Fassnacht M, Ronchi CL.
    Mol Cell Endocrinol; 2024 Sep 01; 590():112272. PubMed ID: 38759836
    [Abstract] [Full Text] [Related]

  • 28. Bioinformatic analyses and experimental validation of the role of m6A RNA methylation regulators in progression and prognosis of adrenocortical carcinoma.
    Xu F, Guan Y, Ma Y, Xue L, Zhang P, Yang X, Chong T.
    Aging (Albany NY); 2021 Apr 21; 13(8):11919-11941. PubMed ID: 33952721
    [Abstract] [Full Text] [Related]

  • 29. Insulin-Like Growth Factor and SLC12A7 Dysregulation: A Novel Signaling Hallmark of Non-Functional Adrenocortical Carcinoma.
    Brown TC, Nicolson NG, Stenman A, Juhlin CC, Gibson CE, Callender GG, Korah R, Carling T.
    J Am Coll Surg; 2019 Sep 21; 229(3):305-315. PubMed ID: 31034883
    [Abstract] [Full Text] [Related]

  • 30. STMN1 is Overexpressed in Adrenocortical Carcinoma and Promotes a More Aggressive Phenotype In Vitro.
    Aronova A, Min IM, Crowley MJP, Panjwani SJ, Finnerty BM, Scognamiglio T, Liu YF, Whitsett TG, Garg S, Demeure MJ, Elemento O, Zarnegar R, Fahey TJ.
    Ann Surg Oncol; 2018 Mar 21; 25(3):792-800. PubMed ID: 29214451
    [Abstract] [Full Text] [Related]

  • 31. Frequent epigenetic inactivation of RASSF1A by aberrant promoter hypermethylation in human gastric adenocarcinoma.
    Byun DS, Lee MG, Chae KS, Ryu BG, Chi SG.
    Cancer Res; 2001 Oct 01; 61(19):7034-8. PubMed ID: 11585730
    [Abstract] [Full Text] [Related]

  • 32. Promoter methylation of MGMT, MLH1 and RASSF1A tumor suppressor genes in head and neck squamous cell carcinoma: pharmacological genome demethylation reduces proliferation of head and neck squamous carcinoma cells.
    Koutsimpelas D, Pongsapich W, Heinrich U, Mann S, Mann WJ, Brieger J.
    Oncol Rep; 2012 Apr 01; 27(4):1135-41. PubMed ID: 22246327
    [Abstract] [Full Text] [Related]

  • 33. Characterization of differential gene expression in adrenocortical tumors harboring beta-catenin (CTNNB1) mutations.
    Durand J, Lampron A, Mazzuco TL, Chapman A, Bourdeau I.
    J Clin Endocrinol Metab; 2011 Jul 01; 96(7):E1206-11. PubMed ID: 21565795
    [Abstract] [Full Text] [Related]

  • 34. Survivin in adrenocortical tumors - pathophysiological implications and therapeutic potential.
    Sbiera S, Kroiss M, Thamm T, Beyer M, Majidi F, Kuehner D, Wobser M, Becker JC, Adam P, Ronchi C, Allolio B, Fassnacht M.
    Horm Metab Res; 2013 Feb 01; 45(2):137-46. PubMed ID: 23143666
    [Abstract] [Full Text] [Related]

  • 35. RASSF1A promoter hypermethylation is a strong biomarker of poor survival in patients with salivary adenoid cystic carcinoma in a Chinese population.
    Zhang CY, Zhao YX, Xia RH, Han J, Wang BS, Tian Z, Wang LZ, Hu YH, Li J.
    PLoS One; 2014 Feb 01; 9(10):e110159. PubMed ID: 25302792
    [Abstract] [Full Text] [Related]

  • 36. CpG island promoter hypermethylation of Ras association domain family 1A gene contributes to gastric carcinogenesis.
    Joo MK, Kim KH, Park JJ, Yoo HS, Choe J, Kim HJ, Lee BJ, Kim JS, Bak YT.
    Mol Med Rep; 2015 Apr 01; 11(4):3039-46. PubMed ID: 25483734
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. TERT promoter hypermethylation is associated with poor prognosis in adrenocortical carcinoma.
    Svahn F, Paulsson JO, Stenman A, Fotouhi O, Mu N, Murtha TD, Korah R, Carling T, Bäckdahl M, Wang N, Juhlin CC, Larsson C.
    Int J Mol Med; 2018 Sep 01; 42(3):1675-1683. PubMed ID: 29956721
    [Abstract] [Full Text] [Related]

  • 39. Sphingosine kinase 1 is overexpressed and promotes adrenocortical carcinoma progression.
    Xu Y, Dong B, Huang J, Kong W, Xue W, Zhu Y, Zhang J, Huang Y.
    Oncotarget; 2016 Jan 19; 7(3):3233-44. PubMed ID: 26673009
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Previous] [Next] [New Search]
    of 19.